Loading...
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
As a consequence of acquired or intrinsic disease resistance, the prognosis for patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) is dismal. Novel, less toxic drugs are clearly needed. One of the most promising emerging therapeutic strategies for cancer treatment is ta...
Na minha lista:
| Udgivet i: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5833263/ https://ncbi.nlm.nih.gov/pubmed/29305553 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-07-794214 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|